BeiGene partners with China’s CSPC for next pipeline asset

Sino-American biotech BeiGene (Nasdaq: BGNE) has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology (HKG: 1093) for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors.

SYH2039 targets solid tumors that have a mutation called MTAP deletion, which is estimated to be present in approximately 15% of all cancer types with the most common including glioblastoma, pancreatic cancer and non-small cell lung cancer.

Lai Wang, global head of R&D at BeiGene, said: “With one of the most dynamic solid tumor portfolios in the industry, we are continually assessing opportunities that align with our strategic focus and address significant unmet needs for patients.